Wolfe Eye Clinic is offering a new, groundbreaking treatment that will affect Iowans who suffer from or are at risk of developing an eye disease that can cause blindness.
On Feb. 17, the U.S. Food and Drug Administration approved the use of Syfovre to treat an advanced form of age-related macular degeneration, Geographic Atrophy (GA).
GA affects more than 1 million people in the U.S. and is a leading cause of blindness in adults over 60. The FDA’s approval is a groundbreaking milestone that will provide – for the first time ever – a treatment for those with GA.
“For more than 100 years, Wolfe Eye Clinic has been Iowa’s leader in the treatment of and research into a wide variety of eye diseases,” said Tom Hurney, chief executive officer of Wolfe Eye Clinic, in a news release. “We will continue to strive every day to meet the needs of our patients, and we are thrilled to be able to offer this new treatment for GA.”
“For years, finding treatments for Geographic Atrophy has been a daunting challenge,” Dr. Jared Nielsen, a Wolfe Eye Clinic retina specialist who participates in clinical trials to provide better care to patients who suffer from sight-threatening retinal diseases, said in a news release. “This great news will positively impact the treatment of our patients with Dry Advanced Macular Degeneration, but the work does not stop here. Our team is dedicated to continuing studies that will help us one day find a cure.”
The Corridor has two main Wolfe Eye Clinic offices, one in Hiawatha at 1195 Boyson Road and in Iowa City at 2225 Mormon Trek Blvd.